|60.80||+0.1400||+0.23%||Vol 817.34K||1Y Perf 132.24%|
|Feb 3rd, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||100.40||Analyst Rating||Strong Buy 1.00|
|Potential %||65.13||Finscreener Ranking||★★★★+ 54.98|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 50.67|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 72.29|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||56.97||Earnings Rating||Strong Buy|
|Market Cap||4.18B||Earnings Date||23rd Feb 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||23rd Feb 2023|
|Estimated EPS Next Report||0.87|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||797.00K|
|Avg. Monthly Volume||898.94K|
|Avg. Quarterly Volume||1.12M|
Lantheus Holdings Inc. (NASDAQ: LNTH) stock closed at 60.8 per share at the end of the most recent trading day (a 0.23% change compared to the prior day closing price) with a volume of 817.34K shares and market capitalization of 4.18B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 595 people. Lantheus Holdings Inc. CEO is Mary Anne Heino.
The one-year performance of Lantheus Holdings Inc. stock is 132.24%, while year-to-date (YTD) performance is 19.31%. LNTH stock has a five-year performance of 177.63%. Its 52-week range is between 25.485 and 87.47, which gives LNTH stock a 52-week price range ratio of 56.97%
Lantheus Holdings Inc. currently has a PE ratio of 32.80, a price-to-book (PB) ratio of 5.23, a price-to-sale (PS) ratio of 4.89, a price to cashflow ratio of 17.80, a PEG ratio of 2.32, a ROA of 11.80%, a ROC of 14.79% and a ROE of 20.18%. The company’s profit margin is 21.92%, its EBITDA margin is 27.00%, and its revenue ttm is $671.89 Million , which makes it $9.76 revenue per share.
Of the last four earnings reports from Lantheus Holdings Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.87 for the next earnings report. Lantheus Holdings Inc.’s next earnings report date is 23rd Feb 2023.
The consensus rating of Wall Street analysts for Lantheus Holdings Inc. is Strong Buy (1), with a target price of $100.4, which is +65.13% compared to the current price. The earnings rating for Lantheus Holdings Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Lantheus Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Lantheus Holdings Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 14.34, ATR14 : 1.85, CCI20 : 157.25, Chaikin Money Flow : 0.28, MACD : 1.69, Money Flow Index : 84.57, ROC : 9.85, RSI : 73.59, STOCH (14,3) : 98.51, STOCH RSI : 1.00, UO : 76.10, Williams %R : -1.49), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Lantheus Holdings Inc. in the last 12-months were: Andrea Sabens (Sold 7 041 shares of value $405 210 ), Brian A. Markison (Option Excercise at a value of $483 320), Brian A. Markison (Sold 43 505 shares of value $3 655 192 ), Carol Walker (Sold 18 129 shares of value $1 003 783 ), Daniel M. Niedzwiecki (Sold 9 142 shares of value $607 993 ), Etienne Montagut (Sold 23 265 shares of value $1 396 427 ), Julie H. McHugh (Sold 7 280 shares of value $509 913 ), Mary Anne Heino (Sold 45 930 shares of value $2 709 378 ), Paul Blanchfield (Sold 6 142 shares of value $312 710 ), Paul M. Blanchfield (Sold 20 786 shares of value $1 162 297 ), Robert J. Marshall (Sold 31 778 shares of value $2 054 859 ), Samuel R. Leno (Option Excercise at a value of $102 482)
Mon, 12 Dec 2022 06:00 GMT Analysts Offer Insights on Healthcare Companies: Lantheus (LNTH) and Better Therapeutics, Inc. (BTTX)- TipRanks. All rights reserved.
Mon, 14 Nov 2022 18:40 GMT Analysts Top Healthcare Picks: Lantheus (LNTH), Gamida Cell (GMDA)- TipRanks. All rights reserved.
Thu, 25 Aug 2022 06:45 GMT Lantheus (LNTH) Receives a Buy from B.Riley Financial- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.